In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment

In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment

To survive and proliferate in solid tumors, cancer cells adapt and evolve rapidly in microenvironments where oxygen and substrate bioavailability fluctuates over time and space. This creates metabolic heterogeneity. Cancer cells can further cooperate metabolically, for example by swapping glycolytic...

Full description

Bibliographic Details
Main Authors: Zohra Benyahia, Marine C. N. M. Blackman, Loïc Hamelin, Luca X. Zampieri, Tania Capeloa, Marie L. Bedin, Thibaut Vazeille, Olivier Schakman, Pierre Sonveaux
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
breast cancer
cancer metabolism
oxidative phosphorylation (OXPHOS)
oxidative pathway of lactate
monocarboxylate transporters (MCTs)
CD147/basigin
Online Access:https://www.mdpi.com/2072-6694/13/3/569

Internet

https://www.mdpi.com/2072-6694/13/3/569

Similar Items